Candidiasis-Pipeline Review, H2 2016

Candidiasis-Pipeline Review, H2 2016


  • Products Id :- GMDHC8343IDB
  • |
  • Pages: 151
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Candidiasis-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Candidiasis-Pipeline Review, H2 2016', provides an overview of the Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Candidiasis

The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects

The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Candidiasis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Candidiasis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Candidiasis Overview 8

Therapeutics Development 9

Pipeline Products for Candidiasis-Overview 9

Pipeline Products for Candidiasis-Comparative Analysis 10

Candidiasis-Therapeutics under Development by Companies 11

Candidiasis-Therapeutics under Investigation by Universities/Institutes 13

Candidiasis-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Candidiasis-Products under Development by Companies 19

Candidiasis-Products under Investigation by Universities/Institutes 22

Candidiasis-Companies Involved in Therapeutics Development 23

Amplyx Pharmaceuticals, Inc. 23

Bakker Medical Srl 24

Biomar Microbial Technologies 25

Biosergen AS 26

Cellceutix Corporation 27

Cidara Therapeutics, Inc. 28

Daewoong Pharmaceutical Co., Ltd. 29

Dermala Inc 30

General Biologicals Corporation 31

Grupo Ferrer Internacional, S.A. 32

Hsiri Therapeutics, LLC 33

iCo Therapeutics Inc. 34

Matinas BioPharma Holdings, Inc. 35

Nanomerics Ltd 36

Novabiotics Limited 37

NovaDigm Therapeutics, Inc. 38

Onxeo SA 39

Scynexis, Inc. 40

Sealife PHARMA GMBH 41

TGV-Laboratories 42

Viamet Pharmaceuticals, Inc. 43

Wellstat Vaccines, LLC 44

Candidiasis-Therapeutics Assessment 45

Assessment by Monotherapy Products 45

Assessment by Combination Products 46

Assessment by Target 47

Assessment by Mechanism of Action 49

Assessment by Route of Administration 51

Assessment by Molecule Type 53

Drug Profiles 55

(clotrimazole + diclofenac sodium)-Drug Profile 55

(clotrimazole + diclofenac sodium) 1-Drug Profile 56

61894700-Drug Profile 57

AC-17-Drug Profile 58

amphotericin B-Drug Profile 59

amphotericin B-Drug Profile 61

amphotericin B-Drug Profile 64

Antibody to Target Ece1 for Candidiasis-Drug Profile 65

APX-001-Drug Profile 66

arasertaconazole-Drug Profile 67

BSG-005-Drug Profile 68

candidiasis vaccine-Drug Profile 69

CD-101-Drug Profile 70

Cellullar Immunotherapy for Viral Infections and Fungal Infections-Drug Profile 73

CTIX-1502-Drug Profile 74

Drug for Candidiasis-Drug Profile 75

DWP-06081-Drug Profile 76

Forazoline A-Drug Profile 77

iCo-010-Drug Profile 78

KSL-W-Drug Profile 79

MH-010-Drug Profile 80

miconazole nitrate-Drug Profile 81

Monoclonal Antibodies for Candidiasis-Drug Profile 83

Monoclonal Antibody for Candidiasis-Drug Profile 84

Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections-Drug Profile 85

Monoclonal Antibody to Inhibit the Beta-Glucan for Fungal Infections-Drug Profile 86

mutanobactins-Drug Profile 87

Myc-102-Drug Profile 88

NDV-3-Drug Profile 89

NDV-3A-Drug Profile 91

NP-339-Drug Profile 92

obliquumol-Drug Profile 93

Occidiofungin-Drug Profile 94

PAC-113-Drug Profile 95

PMX-1408-Drug Profile 97

PMX-1570-Drug Profile 98

PMX-1576-Drug Profile 99

PMX-1591-Drug Profile 100

PMX-1625-Drug Profile 101

PMX-519-Drug Profile 102

PMX-70004-Drug Profile 103

Recombinant Peptides for Oropharyngeal Candidiasis-Drug Profile 104

SCY-078-Drug Profile 105

SLP-0901-Drug Profile 108

SLP-0904-Drug Profile 109

Small Molecule for Bacterial Vaginosis and Candidiasis-Drug Profile 110

Small Molecule for Fungal Infections-Drug Profile 111

Small Molecules for Aspergillosis and Candidiasis-Drug Profile 112

Small Molecules for Candidiasis-Drug Profile 113

Small Molecules for Candidiasis-Drug Profile 114

Small Molecules for Candidiasis-Drug Profile 115

Small Molecules for Fungal Infections-Drug Profile 116

Small Molecules for Fungal Infections-Drug Profile 117

Small Molecules for Systemic Candidiasis-Drug Profile 118

Synthetic Peptide to Inhibit CBL-B for Candidiasis-Drug Profile 119

Synthetic Peptides for Candidiasis-Drug Profile 120

Synthetic Peptides for Infections Diseases and Oncology-Drug Profile 121

TOL-463-Drug Profile 122

Vaccine for Fungal Infections-Drug Profile 123

Vaccine to Target Ece1 for Candidiasis-Drug Profile 124

VT-1161-Drug Profile 125

Candidiasis-Dormant Projects 129

Candidiasis-Discontinued Products 133

Candidiasis-Product Development Milestones 134

Featured News & Press Releases 134

Appendix 145

Methodology 145

Coverage 145

Secondary Research 145

Primary Research 145

Expert Panel Validation 145

Contact Us 145

Disclaimer 146

List of Tables

Number of Products under Development for Candidiasis, H2 2016 14

Number of Products under Development for Candidiasis-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Development, H2 2016 22

Comparative Analysis by Unknown Stage Development, H2 2016 23

Products under Development by Companies, H2 2016 24

Products under Development by Companies, H2 2016 (Contd..1) 25

Products under Development by Companies, H2 2016 (Contd..2) 26

Products under Investigation by Universities/Institutes, H2 2016 27

Candidiasis-Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016 28

Candidiasis-Pipeline by Bakker Medical Srl, H2 2016 29

Candidiasis-Pipeline by Biomar Microbial Technologies, H2 2016 30

Candidiasis-Pipeline by Biosergen AS, H2 2016 31

Candidiasis-Pipeline by Cellceutix Corporation, H2 2016 32

Candidiasis-Pipeline by Cidara Therapeutics, Inc., H2 2016 33

Candidiasis-Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 34

Candidiasis-Pipeline by Dermala Inc, H2 2016 35

Candidiasis-Pipeline by General Biologicals Corporation, H2 2016 36

Candidiasis-Pipeline by Grupo Ferrer Internacional, S.A., H2 2016 37

Candidiasis-Pipeline by Hsiri Therapeutics, LLC, H2 2016 38

Candidiasis-Pipeline by iCo Therapeutics Inc., H2 2016 39

Candidiasis-Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 40

Candidiasis-Pipeline by Nanomerics Ltd, H2 2016 41

Candidiasis-Pipeline by Novabiotics Limited, H2 2016 42

Candidiasis-Pipeline by NovaDigm Therapeutics, Inc., H2 2016 43

Candidiasis-Pipeline by Onxeo SA, H2 2016 44

Candidiasis-Pipeline by Scynexis, Inc., H2 2016 45

Candidiasis-Pipeline by Sealife PHARMA GMBH, H2 2016 46

Candidiasis-Pipeline by TGV-Laboratories, H2 2016 47

Candidiasis-Pipeline by Viamet Pharmaceuticals, Inc., H2 2016 48

Candidiasis-Pipeline by Wellstat Vaccines, LLC, H2 2016 49

Assessment by Monotherapy Products, H2 2016 50

Assessment by Combination Products, H2 2016 51

Number of Products by Stage and Target, H2 2016 53

Number of Products by Stage and Mechanism of Action, H2 2016 55

Number of Products by Stage and Route of Administration, H2 2016 57

Number of Products by Stage and Molecule Type, H2 2016 59

Candidiasis-Dormant Projects, H2 2016 134

Candidiasis-Dormant Projects (Contd..1), H2 2016 135

Candidiasis-Dormant Projects (Contd..2), H2 2016 136

Candidiasis-Dormant Projects (Contd..3), H2 2016 137

Candidiasis-Discontinued Products, H2 2016 138

List of Figures

Number of Products under Development for Candidiasis, H2 2016 14

Number of Products under Development for Candidiasis-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Products, H2 2016 22

Assessment by Monotherapy Products, H2 2016 50

Number of Products by Top 10 Targets, H2 2016 52

Number of Products by Stage and Top 10 Targets, H2 2016 52

Number of Products by Top 10 Mechanism of Actions, H2 2016 54

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 54

Number of Products by Routes of Administration, H2 2016 56

Number of Products by Stage and Routes of Administration, H2 2016 56

Number of Products by Top 10 Molecule Types, H2 2016 58

Number of Products by Stage and Top 10 Molecule Types, H2 2016 58

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Amplyx Pharmaceuticals, Inc.

Bakker Medical Srl

Biomar Microbial Technologies

Biosergen AS

Cellceutix Corporation

Cidara Therapeutics, Inc.

Daewoong Pharmaceutical Co., Ltd.

Dermala Inc

General Biologicals Corporation

Grupo Ferrer Internacional, S.A.

Hsiri Therapeutics, LLC

iCo Therapeutics Inc.

Matinas BioPharma Holdings, Inc.

Nanomerics Ltd

Novabiotics Limited

NovaDigm Therapeutics, Inc.

Onxeo SA

Scynexis, Inc.

Sealife PHARMA GMBH

TGV-Laboratories

Viamet Pharmaceuticals, Inc.

Wellstat Vaccines, LLC

Candidiasis Therapeutic Products under Development, Key Players in Candidiasis Therapeutics, Candidiasis Pipeline Overview, Candidiasis Pipeline, Candidiasis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143120
Site License
USD 4000 INR 286240
Corporate User License
USD 6000 INR 429360

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com